A Simple Clinical Pre-procedure Risk Model for Predicting Thrombocytopenia Associated With Periprocedural Use of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention
Background: No risk model for predicting thrombocytopenia associated with periprocedural tirofiban exposure is available. The purpose of this study was to develop a simple clinical pre-procedure risk model based on pre-procedural characteristics for early prediction of thrombocytopenia before patien...
Main Authors: | Yi-Hu Yi, Wen-Jun Yin, Zhi-Chun Gu, Wei-Jin Fang, Dai-Yang Li, Can Hu, Kun Liu, Rong-Rong Ma, Ling-Yun Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.01456/full |
Similar Items
-
Tirofiban Induced Thrombocytopenia: A Rare but Severe Adverse Effect
by: Muhammad Shabbir Rawala, et al.
Published: (2020-03-01) -
High bolus tirofiban vs abciximab in acute STEMI patients undergoing primary PCI - The tamip study
by: Mohammed A Balghith
Published: (2012-01-01) -
Effect of intracoronary sodium nitroprusside and tirofiban injection on myocardial injury in patients with no reflow in PCI
by: Xiang-Yang Xia
Published: (2018-04-01) -
A meta-analysis of randomized controlled trials investigating tirofiban combined with conventional drugs by intracoronary administration for no-reflow prevention
by: Qian Zeng, et al.
Published: (2020-12-01) -
Antiplatelet medications in acute coronary syndromes and percutaneous coronary interventions: focus on tirofiban
by: T. A. Batyraliev, et al.
Published: (2008-12-01)